<DOC>
	<DOCNO>NCT00490789</DOCNO>
	<brief_summary>The purpose study determine safety efficacy mTOR inhibitor sirolimus treatment renal angiomyolipomas patient tyberous sclerosis complex sporadic lymphangioleiomyomatosis .</brief_summary>
	<brief_title>Trial Efficacy Safety Sirolimus Tuberous Sclerosis LAM</brief_title>
	<detailed_description>Inherited mutation TSC1 TSC2 gene cause tuberous sclerosis acquire ( somatic ) mutation either gene associate sporadic lymphangioleiomyomatosis ( LAM ) . Renal angiomyolipomas feature disorder . TSC1 TSC2 regulate signal mammalian target rapamycin ( mTOR ) pathway . Inhibition mTOR may result decrease size TSC 1/2 assciated lesion . We treat patient tuberous sclerosis sporadic LAM mTOR inhibitor rapamycin non-randomised , open label pilot study safety efficacy . Change size renal angiomyolipomas primary end point</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Tuberous Sclerosis</mesh_term>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>If female , documentation negative pregnancy test prior enrolment . Participants , include male , must use effective form contraception , whilst take sirolimus twelve week stop drug One renal angiomyolipomata least two centimetre great large diameter Adequate renal function : glomerular filtration rate &gt; 40 ml/min Clinically definite diagnosis tuberous sclerosis ( modify Gomez criterion ) sporadic LAM ( biopsyproven compatible high resolution chest CT scan respiratory function test . ) Signed date informed consent History noncompliance inability give inform consent Significant haematological hepatic abnormality ( i.e . transaminase level &gt; 150 i.u./L serum albumin &lt; 30 g/L , haematocrit &lt; 30 % , platelet &lt; 100,000/ mm3 , adjust absolute neutrophil count &lt; 1,500/mm3 , total WBC &lt; 3,000/ mm3 ) Greater 1 g proteinuria daily Multiple bilateral AMLs , individual lesion distinguish Renal haemorrhage within precede year In renal haemorrhage , know conservatively manage renal aneurysm ( ) great 10mm Patients embolisation AML ( ) within precede 6 month Patients unable walk 100 metre flat Continuous requirement supplemental oxygen Patients consider organ transplant Uncontrolled hyperlipidaemia Intercurrent infection initiation Sirolimus Surgery within last 2 month Pregnant lactate woman Use investigational drug within last 30 day Change anti epileptic drug medication within last 3 month Likely need vaccination e.g . travel course trial ( except influenza vaccine patient LAM ) Current usage strong inhibitor CYP3AE ( ketoconazole , voriconazole , itraconazole , tilithromycin clarithromycin ) strong inducer ( rifampicin rifabutin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>tuberous sclerosis</keyword>
	<keyword>lymphangioleiomyomatosis</keyword>
	<keyword>sirolimus</keyword>
	<keyword>angiomyolioma</keyword>
	<keyword>rapamycin</keyword>
	<keyword>mTOR</keyword>
</DOC>